Skip to main content
Premium Trial:

Request an Annual Quote

Compugen s Q2 Revenues Fall by Half; Grants Comprise Brunt of Top-Line Growth

NEW YORK, July 27 (GenomeWeb News) - Compugen today said that second-quarter revenues fell by more than half as R&D spending and net losses remained flat.


Total receipts for the three months ended June 30 fell to $474,000 from $984,000 year over year.  Around $70,000 of the receipts during the current period was actual revenue, with the remainder, around $474,000, coming from "government and other grants," the company said.


Second-quarter R&D spending remained flat at around $3 million, Compugen said.


Net loss for the quarter was also flat at around $3.3 million, or $.12 per share.


Compugen said it had around $19.8 million in cash, equivalents, short-term cash deposits, and marketable securities as of June 30.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.